Baron Financials ETF on Alkermes
Thesis
Baird added Alkermes as part of its increased exposure to commercial-stage therapeutics. The fund highlights Alkermes as one of a small number of companies with a leading product in the Orexin receptor category. Baird believes this category has promising growth potential in wakefulness and potentially additional indications.
“Alkermes is one of a few companies with a lead product in the Orexin receptor category”